Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus

M. A. Vickers, R. Satyanarayana

Research output: Contribution to journalArticlepeer-review

78 Scopus citations

Abstract

Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, has become a first-line therapy for diabetic patients with erectile dysfunction (ED). The efficacy in this subgroup, based on the Global Efficacy Question, is 56% vs 84% in a selected group of non-diabetic men with ED. Two novel PDE5 inhibitors, tadalafil (Lilly ICOS) and vardenafil (Bayer), have recently completed efficacy and safety clinical trials in 'general' and diabetic study populations and are now candidates for US FDA approval. A summary analysis of the phase three clinical trials of sildenafil, tadalafil and vardenafil in both study populations is presented to provide a foundation on which the evaluation of the role of the individual PDE5 inhibitors for the treatment of patients with ED and DM can be built.

Original languageEnglish (US)
Pages (from-to)466-471
Number of pages6
JournalInternational Journal of Impotence Research
Volume14
Issue number6
DOIs
StatePublished - Dec 2002
Externally publishedYes

Keywords

  • Diabetes mellitus
  • Erectile dysfunction
  • Phosphodiesterase inhibitor
  • Sildenafil
  • Tadalafil
  • Vardenafil

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus'. Together they form a unique fingerprint.

Cite this